Dov 21,947 is company’s lead triple reuptake inhibitor, or TRIP, for the treatment of depression and obesity. The clinical trial, which will randomize approximately 200 patients, will evaluate the efficacy and safety of Dov 21,947 over a six-week period.
The primary endpoint of the study is the change in the Montgomery-Asberg Depression Rating Scale from baseline to end of treatment in evaluable patients. Dov expects to announce study results as early as the fourth quarter of 2008.